Structural and In Vitro Functional Analyses of Novel Plant-Produced Anti-Human PD1 Antibody

Kaewta Rattanapisit1,2, Tanapati Phakham3,4, Supranee Buranapraditkun5,6, Konlavat Siriwattanananon1, Chatikorn Boonkrai3,4, Trairak Pisitkun7, Nattiya Hirankarn5, Richard Strasser7, Yoshito Abe8 & Waranyoo Phoolcharoen1,2*

Immunotherapy has emerged as a promising and effective treatment for cancer. The frequently used immunotherapy agents are immune checkpoint inhibitors, such as antibodies specific to PD1, PD-L1, or CTLA-4. However, these drugs are highly expensive, and most people in the world cannot access the treatment. The development of recombinant protein production platforms that are cost-effective, scalable, and safe is needed. Plant platforms are attractive because of their low production cost, speed, scalability, lack of human and animal pathogens, and post-translational modifications that enable them to produce effective monoclonal antibodies. In this study, an anti-PD1 IgG4 monoclonal antibody (mAb) was transiently produced in Nicotiana benthamiana leaves. The plant-produced anti-PD1 mAb was compared to the commercial nivolumab produced in CHO cells. Our results showed that both antibodies have similar protein structures, and the N-glycans on the plant-produced antibody lacks plant-specific structures. The PD1 binding affinity of the plant-produced and commercial nivolumab, determined by two different techniques, that is, enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR), are also comparable. Plant-produced nivolumab binds to human PD1 protein with high affinity and specificity, blocks the PD-1/PD-L1 interaction, and enhances T cell function, comparable to commercial nivolumab. These results confirmed that plant-produced anti-PD1 antibody has the potential to be effective agent for cancer immunotherapy.

Immunotherapy is currently a promising cancer treatment that activates the immune system and alleviates the suppression of the immune system by the tumour. The blockade of immune checkpoints is one of the most efficient approaches for activating anti-tumour immunity. There are 7 immune checkpoint inhibitors approved by USFDA1 including nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, cemiplimab, and ipilimumab. However, these drugs are highly expensive2,3. Most people cannot afford to access this treatment. Therefore, it is necessary to develop novel platforms that are cost-effective, scalable, and safe.

Comparing to current antibody production platforms, plants offer several advantages for producing antibodies over others. Plants have significantly lower infrastructure and raw material cost for upstream production compared to mammalian cells4,5. Plants-based system can do greater scalability because there is no restriction on the fermenter size. The scalability can increase easily by growing more plants6. For the speed of production, transient plant-based technology can produce large amount of protein rapidly7. Moreover, antibodies produced in plants are not prone to contamination with human or animal pathogens. Plant cells efficiently assemble...
complexed proteins, such as antibodies, and perform necessary posttranslational modifications. Plant-produced recombinant proteins were shown to meet the same good manufacturing practice criteria as proteins produced in mammalian cells, such as appearance, stability, half-life, immunogenicity etc. These advantages for plant platforms suggest that they represent an attractive alternative for producing biopharmaceuticals for developing countries.

In this study, we further developed an anti-PD1 monoclonal antibody (mAb), nivolumab, as a possible cancer immunotherapeutic by applying plant technology that enables cost-effective and scalable antibody production. We produced nivolumab at 140 μg/g fresh Nicotiana benthamiana leaves within 6 days of infiltration. Plant-produced nivolumab retained similar structure and in vitro efficacy, compared to those of commercial mammalian cell-produced nivolumab. This study is the first to demonstrate the use of plant-derived mAb for cancer immunotherapy.

Results

Expression and purification of anti-PD1 monoclonal antibodies in ΔXF N. benthamiana. To increase the yield of monoclonal antibody (mAb) expression in plants, the coding sequences of the heavy chain (HC) and light chain (LC) of nivolumab were optimized in silico with N. benthamiana-optimized codon, cloned into geminiviral vectors and transformed into Agrobacterium tumefaciens. A. tumefaciens harbouring pBY-Nivo-HC and pBYNivo-LC (Fig. 1A) were co-delivered into N. benthamiana leaves through vacuum infiltration. Co-expression of the HC and LC resulted in the assembly of the complete antibody consisting of 2HC and 2LC (Fig. 1B). The expressed antibody was purified using protein A affinity chromatography and subjected to SDS-PAGE. The nonreducing SDS-PAGE confirmed that the complete mAb assembled into its tetrameric form (Fig. 1C). The reducing gel electrophoresis confirmed that the HC and LC of anti-PD1 mAb were expressed in leaves with the expected molecular weights (Fig. 1D). Notably, differences in mobility are caused by the presence of the SEKDEL peptide on the HC and LC. Western blot analysis after reducing gel electrophoresis confirmed the expression of HC and LC with anti-human gamma and anti-human kappa antibodies (Fig. 1E,F, respectively). Moreover, the purified antibody was analyzed by size exclusion chromatography. The result confirmed that the purified plant-produced monoclonal antibody remains monomer as commercial nivolumab (Fig. 1G). The assembly of anti-PD1 mAb was confirmed by an ELISA that detects the assembled form of the antibody. ELISA results also showed that the anti-PD1 mAb was expressed at the highest levels on 6 dpi, producing approximately 140 μg/g leaf fresh weight (Fig. 2).

Plant-produced anti-PD1 exhibited mammalian-like N-linked glycosylation patterns. The N-glycan composition of the plant-produced nivolumab was compared to commercial CHO cell-produced antibody by liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS) analysis of tryptic glycopeptides (Fig. 3). As expected, the results confirmed that the N-glycan composition of nivolumab...
produced in ΔXF plants contained mainly GnGn (GlcNAc2Man3GlcNAc2) structures that more closely resemble mammalian-type N-glycans. As expected, GnGnF (GlcNAc2Man3FucGlcNAc2) carrying the mammalian-specific core fucosylation was the major N-glycosylated peptide in the commercial CHO cell-produced antibody (Fig. 3).

Secondary and tertiary structural characterization. The secondary and tertiary structures of plant-produced anti-PD1 were compared to commercial mammalian cell-produced antibody using circular dichroism (CD) and nuclear magnetic resonance (NMR) spectroscopy, respectively. The CD results (Fig. 4A) confirmed that the secondary structure of plant-produced anti-PD1 is similar to that of the commercial antibody. Both spectra indicate negative absorbance at 218 nm, which is a β-sheet-rich structure. For NMR spectroscopy, dispersed aromatic protons (Fig. 4B) and up-fielded methyl protons (Fig. 4C) were observed in both spectra, indicating that the tertiary structures are retained. Furthermore, both NMR spectra also confirmed that the tertiary structure of the plant-produced anti-PD1 antibody is similar to that of the commercial antibody.

Functional assays of plant-produced anti-PD1 mAb. The in vitro binding to human PD1 protein of the plant-produced anti-PD1 mAb was determined by ELISA, as shown in Fig. 5A. Both plant cell-produced and commercial mammalian cell-produced anti-PD1 mAbs showed similar binding to human PD1 protein. Atezolizumab (anti-PDL1 mAb)\textsuperscript{13} and 2C10 (anti-Porcine Epidemic Diarrhea virus (PEDV) mAb)\textsuperscript{14} were used as the negative control. Both anti-PD1 mAbs could not bind to human PDL1 protein (Fig. 5B).

To assess the binding of the antibody more quantitatively, a surface plasmon resonance (SPR) assay was performed with purified plant-produced or commercial mammalian cell-produced anti-PD1 mAb immobilized on
a Protein G sensor chip. The human PD1 protein was generated and flowed across the solid-phase anti-PD1 mAb at various concentrations. Plant-produced anti-PD1 mAb showed similar binding affinity and kinetics for human PD1 protein compared to commercial mammalian cell-produced mAb (Fig. 6). The association rate constant $k_a$, dissociation rate constant $k_d$, and equilibrium dissociation constant $K_D$ of the plant-produced and commercial

Figure 4. Structural analysis of plant-produced anti-PD1 and commercial mammalian cell-produced antibodies. (A) Plant-produced anti-PD1 antibody (solid line) and commercial mammalian cell-produced antibody (dashed line) in PBS (pH 7.4) were scanned by a circular dichroism spectrometer from 200–250 nm at room temperature. Both proteins exhibited a maximum wavelength at 218 nm. (B,C) NMR spectra in (B) aromatic region and (C) methyl region of commercial mammalian cell produced antibody (upper) and plant-produced anti-PD1 (lower) in PBS buffer (pH 7.4) containing 10% v/v D$_2$O at 25 °C are shown, respectively.

Figure 5. Specific binding to human PD-1 is confirmed by indirect ELISA. Serial dilutions of monoclonal antibodies (Plant-produced nivolumab, Commercial nivolumab, Commercial atezolizumab, Plant-produced PEDV mAb) were incubated on plates coated with human PD-1 (A) or human PD-L1 (B) proteins and detected with HRP-conjugated anti-human IgG antibody. Commercial atezolizumab (anti-PD-L1) and plant-produced PEDV mAb were used as negative control in PD1 binding assay (A). Commercial atezolizumab was used as positive control in PDL1 binding assay (B). The absorbance at 492 nm (mean ± SD) from triplicates are presented.
nivolumab are detailed in Table 1. The K_D between human PD1 and the plant-produced and commercial antibodies are 14 nM and 12 nM, respectively (Table 1). This data confirmed that both mAbs can bind to human PD1 protein with high affinity similarly.

Using a luciferase reporter system, where luciferase expression is under the control of an nuclear factor of activated T-cell (NFAT) promoter, plant-produced anti-PD1 mAb induced concentration-dependent NFAT activation, similar to the commercial mammalian cell-produced antibody, with EC50 values of 496 ng/ml and 544 ng/ml, respectively, being observed (Fig. 7). Human IgG was used as a negative control in this study.

The ability of plant-produced anti-PD1 mAb to promote T cell responses was measured in vitro. The human PBMCs were stimulated by the Staphylococcal enterotoxin B in the presence of 1 μg/ml anti-PD1 mAb. Plant-produced nivolumab enhanced both IL-2 (Fig. 8A) and IFN-γ (Fig. 8B) secretion, comparing to human IgG4 negative control. In addition, the levels of IL-2 and IFN-γ enhancing from the activation of plant-produced nivolumab are not significantly different from commercial nivolumab. These experiments showed that

### Table 1. Kinetic parameters and affinity determination of plant-produced and commercial nivolumab binding to human PD1 protein.

| Ligand              | ka (1/Ms) | kd (1/s) | KD (M)   |
|---------------------|-----------|----------|----------|
| Nivolumab ΔXF       | 1.68e+05  | 2.48e-03 | 1.47e-08 |
| Nivolumab commercial| 1.31e+05  | 1.63e-03 | 1.25e-08 |

Figure 6. Binding affinity measurement of antibodies to human PD-1 protein by SPR (Biacore T200). Sensorgrams of (A) commercial nivolumab (commercial) and (B) nivolumab produced in ΔXF N. benthamiana plants (ΔXF). Human PD-1 protein was injected into the flow cell at various concentrations (10 nM-160 nM) to evaluate the binding/kinetics constants. The equilibrium dissociation constant (K_D) was calculated using a 1:1 Langmuir-binding model.
plant-produced anti-PD1 mAb can bind potently to human PD1 protein, block the PD-1/PD-L1 interaction, and activate T cell response.

**Discussion**

Immunotherapy is an attractive treatment for many cancer patients. In particular, treatment with monoclonal antibody (mAb)-based immune checkpoint blockade enhances the anti-tumour function of T cells, yielding promising results in clinical studies8–11. However, immunotherapy is highly expensive, which could reach up to 1 million US dollars per patient12. Therefore, most people in developing countries cannot access this treatment. Plant platform was developed recently for producing Our goal is to develop an alternative platform for producing effective immune checkpoint blockade mAb. In this study, we investigated the production of anti-human PD1 mAb in plants. Our results show that plant-derived anti-PD1 nivolumab mAb has similar structure and binding potency compared to mammalian cell-produced mAb. Moreover, the plant platform can address the cost and scalability issues associated with antibody production.

Transgenic plants are still prohibited in many countries13. To avoid concerns about genetically modified plants, transient expression technology was used in this study. Plants were recently developed to produce several monoclonal antibodies, which mostly are infectious therapeutic antibodies15–17 and anti-cancer antibodies18–20. Our study firstly showed the development of plant-produced IgG4 monoclonal antibody for immunotherapy. The nivolumab heavy chain and light chain were modified by codon optimization based on the *Nicotiana benthamiana* codon bias. The sequence Ser-Glu-Lys-Asp-Glu-Leu (SEKDEL), the endoplasmic reticulum (ER) retention motif, was added to the C-terminus of the heavy chain. The SEKDEL motif has been shown to increase the recombinant protein levels for some antibodies21. Presumably because the ER is a favorable compartment for protein storage as it lacks proteases that may degrade the recombinant protein.

The nivolumab was rapidly expressed in *N. benthamiana* leaves within 6 days of infiltration and successfully assembled into a native IgG monomer form (Fig. 1C,G). With genetic optimization and ER retention, mAb accumulated at an average of 140 µg/g of fresh leaf weight (Fig. 2). Previous study was shown that the PD1 binding of commercial nivolumab is highly potent14. Compared to the commercial mAb, both ELISA and SPR techniques showed that plant-derived nivolumab has equivalent binding kinetics in vitro.

The N-linked glycosylation of proteins in plants is generally similar to that in mammalian cells, but plants contain specific xylose and fucose residues that are not found in mammals22. Therefore, there is concern about the immunogenicity of plant-specific N-glycans in humans. The clinical data on the immunogenicity of plant-produced anti-PD1 mAb can bind potently to human PD1 protein, block the PD-1/PD-L1 interaction, and activate T cell response.

**Figure 7.** Plant-produced nivolumab blocks the PD-1/PD-1 interaction. The luminescence signal (RLU, relative light unit) at various concentrations starting from 33.33 µg/ml to 5.08 ng/ml of plant-produced nivolumab, commercial nivolumab, human IgG, and plant-produced PEDV mAb14 from three independent experiments are presented as the mean ± SD.

**Figure 8.** PD-1 blockade enhances T cell responses. PBMCs from 4 healthy donors were stimulated with 1 ng/ml Staphylococcal enterotoxin B (SEB) in the presence of 1 µg/ml plant-produced nivolumab, commercial nivolumab and human IgG4 antibody. The media was collected after 3 days for measurement of IL-2 (A) and IFN-γ (B) by ELISA. The amount of IL-2 and IFN-γ from three independent experiments are presented as the mean ± SD.
N-glycans are still controversial\(^{16-18}\). However, several studies showed there is no cases with allergic or hypersensitivity symptoms\(^{22-24}\). For immune checkpoint blockade purposes, the IgG4 subtype was used because the induction of ADCC by IgG4 is notably weak or nonexistent\(^{19}\). This study aims to compare the anti-PD1 mAb produced in plant and mammalian cells.

Therefore, glyco-modified plants that almost completely lack 3,1,2-xylose and core α,1,3-fucose residues on N-glycans were used in this study\(^ {20}\). The N-glycan structure attached to the conserved N-glycosylation site in the heavy chain of nivolumab produced in these plants is not identical to mammalian cell-produced nivolumab (Fig. 3). In particular, the plant-produced antibody lacks core fucosylation and terminal galactosylation and displays oligomannosidic N-glycans (Man5-Man9). The oligomannosidic N-glycans are the result of SEKDEL-mediated retention in the endoplasmic reticulum (ER). The glycan variation in the Fc region of the IgG affects the binding of the Fc receptor and the antibody-dependent cell-mediated cytotoxicity (ADCC)\(^ {26,27}\) and the anti-PD1 IgG4 with oligomannosidic N-glycans may also be subjected to faster in vivo clearance due to binding to the mannose receptors\(^ {28}\). The ADCC of different anti-PD1 IgG4 glycosylation variants as well as the in vivo half-life will be analysed in future results. To this end, the anti-PD1 IgG4 will be produced in wild-type plants containing specific xylose and fucose residues, in AXF plants and without the SEKDEL peptide to reduce the amount of oligomannosidic N-glycans. Without the SEKDEL peptide the recombinant protein will be trafficking through the Golgi apparatus where the N-glycans are processed from oligomannosidic to complex N-glycans\(^ {22}\).

In addition to the glycan structure, the secondary and tertiary structures of the antibody produced from plant and mammalian cells are compared. The data from CD and NMR spectroscopy confirmed that the secondary and tertiary of both antibodies are similar (Fig. 4).

In addition to the glycan and protein structures, the binding efficacy of the antibody is critical. In vitro binding of both antibodies to human PD1 was analysed by ELISA and SPR (Figs 5 and 6). Our results confirm that plant-produced anti-PD1 mAb can bind to human PD1 protein approximately as well as mammalian cell-produced anti-PD1 mAb. To compare the potency and stability of both antibodies, a PD-1/PD1-L1 blockade cell-based bioassay (Promega, USA) was used. Interestingly, our data showed that both antibodies had similar PD-1/PD1-L1 blockade patterns at the same concentration (Fig. 7).

In summary, we established a plant cell-based platform to rapidly express and assemble anti-PD1 IgG4 mAb. Our data also show the similarities in structure and PD1 binding efficacy between plant cell-based and mammalian cell-based antibodies, supporting the potential of plant-produced anti-PD1 mAb for use in cancer immunotherapy. However, human PD1 knock-in mice are needed to study the efficacy of plant-produced anti-PD1 mAb in vivo. From a manufacturing perspective, the production cost of plant-produced mAb is lower than that of the mammalian system. Therefore, a plant-based alternative platform might reduce the cost of the current treatment with mAb-based immune checkpoint blockade.

Methods

Expression vector construction. Nucleotide sequences encoding nivolumab heavy chain (HC) and light chain (LC) were optimized in silico with Nicotiana benthamiana-optimized codons. The signal peptide was added to the N-terminus, and SEKDEL was added to the C-terminus of both HC and LC genes. Optimized HC and LC sequences were synthesized (Bioneer company, South Korea). The nivolumab HC and LC plasmids were cut with SacI and XbaI before ligation into a geminiviral vector\(^ {23}\) resulting in pBYNivo-HC and pBYNivo-LC, respectively (Fig. 1A). The plasmids were transformed into Agrobacterium tumefaciens strain GV3101.

Plant inoculation and protein expression. AXF Nicotiana benthamiana plants\(^ {24}\) were grown in a controlled plant room with a 16 h light/8 h dark cycle at 28 °C for 6 to 8 weeks. Plants were co-agroinfiltrated with GV3101 strains containing pBYNivo-HC or pBYNivo-LC at OD\(_ {600}\) 0.2 by vacuum infiltration. Infiltrated leaves were harvested on 2, 4, 6, 8, and 10 days post-infiltration (dpi) to evaluate the antibody expression pattern. For other experiments, plant leaves were harvested at 6 dpi. A blender was used to homogenize infiltrated leaves with 1x PBS (phosphate-buffered saline: 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na\(_ {2}\)HPO\(_ {4}\), 1.47 mM K\(_ {2}\)HPO\(_ {4}\)) at pH 7.4 and centrifuged at 26,000 g and 4 °C for 40 min. Crude extract was filtered with a 0.45-µm membrane filter and loaded into a protein A bead column. After washing the column with 1x PBS pH 7.4, the protein was eluted with 100 mM glycine pH 2.7 and neutralized with 1.5 M Tris base to final pH value of 7.4.

SDS-PAGE and Western blot analysis. The commercial and purified plant-produced nivolumab antibodies were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE) under non-reducing and reducing conditions. For non-reducing condition, the antibody was mixed with non-reducing loading solution (125 mM Tris–HCl pH 6.8, 12% (w/v) SDS, 10% (v/v) glycerol, 0.001% (w/v) bromophenol blue) and separated on 6–15% SDS–PAGE. For reducing condition, the antibody was mixed with reducing loading solution (125 mM Tris–HCl pH 6.8, 12% (w/v) SDS, 10% (v/v) glycerol, 22% (v/v) β-mercaptoethanol, 0.001% (w/v) bromophenol blue) and separated on 12% SDS–PAGE. The antibodies were either visualized by InstantBlueTM (Expedeon, UK) staining or transferred to nitrocellulose membrane (Bio-Rad, USA). The membrane was blocked with 5% skim milk and probed with HRP-conjugated anti-human gamma antiserum (The Binding Site, UK). The membranes were developed by chemiluminescence using ECL plus detection reagent (Abcam, UK).

Size exclusion chromatography. Fifty microliters of 2 µM protein solution was loaded on a Superdex 200 10/300 GL column (GE Healthcare, Little Chalfont, UK). The protein was eluted with elution buffer (50 mM Tris–HCl pH 7.5 and 150 mM KCl) at a flow rate of 0.3 ml/min. The eluted proteins were detected by the absorbance value at 280 nm.
Antibody quantification by ELISA. The leaves harvested at 2, 4, 6, 8, and 10 dpi were extracted with 1x PBS buffer pH 7.4. A 96-well plate was coated with 50 μl of anti-human IgG-Fc fragment specific (Abcam, UK) 1:1,000 in 1x PBS buffer and incubated overnight at 4°C. The plate was washed three times with 0.05% Tween-20 in PBS (PBST) buffer and blocked with 5% skim milk powder in 1x PBS buffer for 2 h at 37°C. The plate was washed three times with PBST. Diluted human IgG1 kappa isotype antibody (Abcam, UK) or plant crude extracts were added into the well and incubated at 37°C for 2 h. The plate was washed and incubated with 50 μl of HRP-conjugated anti-human kappa antiserum (The Binding Site, UK) 1:1,000 in 1x PBS buffer for 1 h at 37°C. The plate was developed using a TMB mixture (Surmodics, USA). The reaction was stopped by 50 ml of 1 M H2SO4 and measured at 450 nm with CLARIOStar (BMG Labtech, Germany).

N-Glycan analysis. Purified nivolumab was subjected to SDS-PAGE under reducing conditions. The heavy chain was excised from the gel, S-alkylated and digested with trypsin. Liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS) of tryptic glycopeptides was performed as described previously35.

Circular dichroism (CD) spectroscopy. Plant-produced anti-PD1 or commercial mammalian cell-produced antibodies (10 μM) were dissolved in PBS buffer (pH 7.4). CD spectra were collected using a quartz cell with a 1-mm optical path length on a J-720W CD spectropolarimeter (JASCO, Tokyo, Japan) at room temperature. The molar ellipticity expressed in degrees × cm2/dmol was calculated based on a mean residue molecular weight of 110. Each sample was measured in triplicate.

NMR spectroscopy. NMR spectra were recorded on a Varian Unity INOVA 600 spectrometer (Varian, Palo Alto, CA, USA). NMR samples (100 μl) of plant-produced or commercial mammalian cell-produced anti-PD1 antibodies were dissolved in PBS buffer (pH 7.4) containing 10% v/v D2O. Topspin 4.0.2 software (Bruker Corp., MA) was used to process the data.

Human PD-1 binding by ELISA. The binding ability of anti-PD-1 was evaluated by ELISA. Briefly, the MaxiSorp high protein-binding-capacity 96-well ELISA plate was coated with 10 ng/well (100 μl) of recombinant human PD-1 His tag protein at 4°C overnight. The coated ELISA plate was washed 3 times and blocked with PBST. The twofold serial dilution of monoclonal antibodies (Plant-produced nivolumab, Commerical nivolumab15, Commercial atezolizumab36, Plant-produced PDEV mAβ1) in PBS (starting from 200 ng/well, 100 μl) was added to the plate, incubated at 37°C for 1 h, and then washed 3 times with PBST. The goat anti-human IgG-HRP was added (100 μl/well at a 1:10,000 dilution in PBST), incubated at 37°C for 1 h, and washed 3 times with PBST. The OPD substrate solution (100 μl/well) (#P9187, Sigmafast™ OPD) was added to the plate and incubated in the dark at RT for 20 min. The stop solution (50 μL/well, 2 M H2SO4) was added to the plate to stop the reaction, and the absorbance at 492 nm was determined using a Cytation™ 5 cell imaging multi-mode reader.

Kinetics/Affinity analysis by SPR technique. The surface plasmon resonance (SPR) technique was used to assess the binding kinetics/affinity of a purified plant cell-produced antibody to human PD-1 compared to a commercial antibody, nivolumab. The Biacore T200 system with a Protein G sensor chip at 440 RU (10^12 M) were dissolved in PBS buffer (pH 7.4). CD spectra were collected using a quartz cell with a 1-mm optical path length on a J-720W CD spectropolarimeter (JASCO, Tokyo, Japan) at room temper-ature. The molar ellipticity expressed in degrees × cm2/dmol was calculated based on a mean residue molecular weight of 110. Each sample was measured in triplicate.

PD-1/PD-L1 neutralizing activity by PD-1/PD-L1 blockade bioassay. The neutralizing activity of the anti-PD-1 antibody was analysed by a luciferase reporter assay (#1250, PD-1/PD-L1 Blockade Bioassays from Promega) according to the manufacturer’s instructions. Briefly, PD-L1 aAPC/CHO-K1 cells were seeded into a white flat-bottom 96-well assay plate and incubated for 16 h at 37°C in a 5% CO2 humidified incubator. Serial dilutions of purified plant-produced nivolumab or commercial nivolumab were added to the plates followed by seeding PD-1 effector cells. After co-culture for 6 h at 37°C in a 5% CO2 humidified incubator, the Bio-Glo™ reagent was added to the plate and incubated at ambient temperature for 5 min. The luminescence signal was measured using a Cytation™ 5 cell imaging multi-mode reader and reported as relative light units (RLUs), and the data were analysed using GraphPad Prism.

Cytokines production by SEB stimulated PBMCs. Frozen Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors ACB blood by density gradient separation with Isoprep (Robbins Scientific Corporation, Sunnyvale, CA). PBMCs were frozen and stored in Fetal Bovine Serum (FBS) with 10% dimethyl sulfoxide (DMSO), in liquid nitrogen until assay time. On day 0, frozen PBMCs (n = 4) were thawed and seeded at 100,000 cells/well. Cells were cultured with 1 μg/ml of purified plant-produced nivolumab, commercial nivolumab and a human isotype control antibody (hIgG4, Biolegend) in triplicate. All conditions were stimulated with and without Staphylococcal enterotoxin B (SEB) at 1 ng/ml. IL-2 and IFN-γ levels in culture supernatant were performed by ELISA analysis (Biolegend, USA) on day 3.

Statistical analysis. All three independent experiments were performed in this study. Statistical evaluation was performed using GraphPad Software v8.0 (GraphPad Software, San Diego, CA). A nonparametric t-test was used to determine the significance of differences between 2 groups (plant-produced nivolumab and commercial nivolumab) with non-Gaussian distributions. Statistical significance was considered to require a P value lower than 0.05.
References

1. Hargaden, K. M., Johnson, C. E. & Williams, C. J. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. *Int Immunopharmacol* 62, 29–39, https://doi.org/10.1016/j.intimp.2018.06.001 (2018).

2. Adams, K. T. Cancer Immunotherapies—and Their Cost—Take Center Stage at ASCO’s 2015 Annual Meeting. *Manag Care* 24, 30–32 (2015).

3. Tartari, F. et al. Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges. *Cancer Treat Rev* 48, 20–24, https://doi.org/10.1016/j.ctr.2016.06.002 (2016).

4. Nandi, S. et al. Techno-economic analysis of a transient plant-based platform for monoclonal antibody production. *MAbs* 8, 1456–1466, https://doi.org/10.1080/19420866.2016.1227901 (2016).

5. Mir-Artigues, P. et al. A simplified techno-economic model for the molecular pharmaning of antibodies. *Biotechnol Bioeng*, https://doi.org/10.1002/bit.27093 (2019).

6. Buyel, J. F. & Fischer, R. Predictive models for transient protein expression in tobacco (Nicotiana tabacum L.) can optimize process time, yield, and downstream costs. *Biotechnol Bioeng* 109, 2575–2588, https://doi.org/10.1002/bit.24523 (2012).

7. D’Aoust, M. A. et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. *Plant biotechnology journal* 8, 607–619, https://doi.org/10.1111/j.1467-7652.2009.00496.x (2010).

8. Fischer, R., Stoger, E., Schillberg, S., Christou, P. & Tywman, R. M. Plant-based production of biopharmaceuticals. *Curr Opin Plant Biol* 7, 152–158, https://doi.org/10.1016/j.pop.2004.01.007 (2004).

9. Ma, J. K. et al. Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants. *Plant biotechnology journal* 13, 1106–1120, https://doi.org/10.1111/pbi.12416 (2015).

10. Ma, J. K. et al. Plant-derived pharmaceuticals—the road forward. *Trends Plant Sci* 10, 580–585, https://doi.org/10.1016/j.tplants.2005.10.009 (2005).

11. Stoger, E., Fischer, R., Moloney, M. & Ma, J. K. Plant molecular pharming for the treatment of chronic and infectious diseases. *Annu Rev Plant Biol* 65, 743–768, https://doi.org/10.1146/annurev-plant-052113-035850 (2014).

12. Kasamon, L. Y. et al. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma. *Oncologist* 22, 585–591, https://doi.org/10.1634/theoncologist.2017-0004 (2017).

13. Rittmeyer, A. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. *Lancet* 389, 235–245, https://doi.org/10.1016/S0140-6736(16)30237-1 (2017).

14. Rattanapaisit, K. et al. Rapid Transient Production of a Monoclonal Antibody Neutralizing the Porcine Epidemic Diarrhea Virus (PEDV) in Nicotiana benthamiana and Lactuca sativa. *Planta Med* 83, 1412–1419, https://doi.org/10.1055/s-0043-112344 (2017).

15. Lai, H. et al. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity. *Vaccine* 36, 1846–1852, https://doi.org/10.1016/j.vaccine.2018.02.073 (2018).

16. Huang, Z. et al. High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replication system. *Biotechnol Bioeng* 106, 9–17, https://doi.org/10.1002/bit.22653 (2010).

17. Tsekoa, T. L. et al. Efficient In Vitro and In Vivo Activity of Glyco-Engineered Plant-Produced Rabies Monoclonal Antibodies E559 and 62-71-3. *PloS one* 11, e0159313, https://doi.org/10.1371/journal.pone.0159313 (2016).

18. Kominneni, V. et al. In Vivo Glycan Engineering via the Mannosidase I Inhibitor (Kifunensine) Improves Efficacy of Rituximab Manufactured in Nicotiana benthamiana Plants. *Int J Mol Sci* 20, https://doi.org/10.3390/ijms20010194 (2019).

19. Komarova, T. V. et al. Trastuzumab and Pertuzumab Plant Biosimilars: Modification of Asn297-linked Glycan of the mAbs Produced in a Plant with Fuscosyltransferase and Xylosyltransferase Gene Knockouts. *Biochemistry (Mosc)* 82, 510–520, https://doi.org/10.1134/S0006297719040137 (2017).

20. Brodzik, R. et al. Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells. *Proceedings of the National Academy of Sciences of the United States of America* 103, 8804–8809, https://doi.org/10.1073/pnas.0603043103 (2006).

21. Petrucelli, S. et al. A KDEL-tagged monoclonal antibody is efficiently retained in the endoplasmic reticulum in leaves, but is both partially secreted and sorted to protein storage vacuoles in seeds. *Plant biotechnology journal* 4, 511–527, https://doi.org/10.1111/j.1365-7652.2006.00200.x (2006).

22. Strasser, R. Plant protein glycosylation. *Glycobiology* 26, 926–939, https://doi.org/10.1093/glycob/cwv023 (2016).

23. Gicheshe, J. A. et al. Safety and immunogenicity of a plant-produced Pvu25-kb virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults. *Vaccine* 36, 5865–5871, https://doi.org/10.1016/j.vaccine.2018.08.033 (2018).

24. Pillet, S. et al. Immunogenicity and safety of a quadrivalent plant-derived virus-like particle vaccine candidate—Two randomized Phase II clinical trials in 18 to 49 and >/=50 years old adults. *PloS one* 14, e0216333, https://doi.org/10.1371/journal.pone.0216333 (2019).

25. Ward, B. J. et al. Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines. *Vaccine* 32, 6098–6106, https://doi.org/10.1016/j.vaccine.2014.08.079 (2014).

26. Marusic, C. et al. N-glycan engineering of a plant-produced anti-CD20-hIL-2 immunocytokine significantly enhances its effector functions. *Biotechnol Bioeng* 115, 565–576, https://doi.org/10.1002/bit.26503 (2018).

27. Hiatt, A. et al. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. *Proceedings of the National Academy of Sciences of the United States of America* 111, 5992–5997, https://doi.org/10.1073/pnas.1402458111 (2014).

28. Goetzke, A. M. et al. High-mannose glycans on the Fc region of therapeutically IgG antibodies increase serum clearance in humans. *Glycobiology* 21, 949–959, https://doi.org/10.1093/glycob/cwr027 (2011).

29. Strasser, R. et al. Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. *Plant biotechnology journal* 6, 392–402, https://doi.org/10.1111/j.1467-7652.2008.00330.x (2008).

30. Ning, Y. M. et al. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy. *Oncologist* 22, 743–749, https://doi.org/10.1634/theoncologist.2017-0087 (2017).

Acknowledgements

This work was supported by Grant No. P-18-50128 from the National Science and Technology Development Agency (NSTDA) and the Chulalongkorn Academic Advancement into Its Second Century (CUAAC) Project. KR was supported by the Ratchadapiseksomphot Fund, Chulalongkorn University for the Postdoctoral Fellowship. We thank Dr. Hugh Mason (Center for Immunotherapy, Vaccines, and Virotherapy, Biodesign Institute, School of Life Sciences, Arizona State University, Tempe, Arizona, United States) for providing...
geminiviral vectors. We thank Dr. Herta Steinkellner (Department of Applied Genetics and Cell Biology, University of Natural Resources and Life Sciences, Vienna, Austria) for providing ΔXF plants and Dr. Clemens Grünwald-Gruber (Department of Chemistry, University of Natural Resources and Life Sciences, Vienna, Austria) for assisting with LC-ESI-MS analysis.

**Author contributions**

K.R., T.P., N.H., and W.P. conceived of and designed the study. K.R., T.P., S.B., K.S., C.B., R.S., and Y.A. performed experiments. K.R., T.P., T.P., N.H., R.S., Y.A., and W.P. analysed data. K.R., T.P., T.P., R.S., Y.A., and W.P. wrote the manuscript. All authors reviewed the manuscript.

**Competing interests**

The authors declare no competing interests.

**Additional information**

Correspondence and requests for materials should be addressed to W.P.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019